This weekly update in vaccines and immunotherapy covers recent developments across clinical research, regulatory decisions, and real-world effectiveness studies. The update highlights progress in preventive vaccines, early and late-stage oncology vaccine programs, and comparative safety and tolerability data. It reflects ongoing expansion of vaccine platforms across infectious diseases and cancer indications.
In Today’s Newsletter
Dive deeper
🧬 RSV maternal vaccine reduces infant hospital admissions [1] [UK • 17 Apr 2026]
https://www.gov.uk/government/news/rsv-maternal-vaccine-cuts-baby-hospital-admissions-by-up-to-85
Context: Analysis covered births between Sep 2024 and Mar 2025, with >4,500 RSV hospitalisations recorded.
Key point: Maternal RSV vaccination showed ~81% effectiveness against infant hospitalisation, rising to ~85% when vaccination occurred ≥4 weeks before birth (UKHSA real-world dataset ~300,000 births).
Implication: May strengthen antenatal vaccination uptake and timing adherence in public health programmes.
🧪 Personalized mRNA pancreatic cancer vaccine linked to long-term survival [2] [19 Apr 2026]
https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out
Context: Vaccine was individualized using tumor mutation profiling and combined with chemotherapy and checkpoint inhibition.
Key point: Phase 1 study (n=16) of autogene cevumeran showed 87.5% of immune responders alive at 4–6 years post-treatment.
Implication: May support continued expansion of personalized mRNA immunotherapy in solid tumors.
🦠 Chikungunya vaccine shows durable immune response in Phase 1 [3] [20 Apr 2026]
https://www.ambimed-group.com/en/ambimed-per-le-aziende/risultati-promettenti-da-uno-studio-sperimentale-per-il-vaccino-contro-la-chikungunya
Context: No vaccine-related serious adverse events reported; single-dose regimen evaluated.
Key point: Valneva VLA1553 Phase 1 trial (n=120) showed 100% seroconversion by day 14 and sustained antibody responses at 12 months.
Implication: May support advancement into late-stage efficacy trials for mosquito-borne disease prevention.
🧬 AI-designed melanoma vaccine shows strong immune activation [4] [17 Apr 2026]
https://evaxion.ai/investors/?press_release_id=11106
Context: Personalized vaccine combined with pembrolizumab; study reports durable immune responses and 75% objective response rate (previous data).
Key point: EVX-01 Phase 2 data show 86% of vaccine targets triggered tumor-specific immune responses in advanced melanoma.
Implication: May support broader use of AI-based antigen selection in oncology vaccine design.
💉 COVID vaccine tolerability comparison favors protein-based platform [5] [18 Apr 2026]
https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-18-10-00-00-3276558
Context: Fewer severe systemic reactions (under 1 in 10 vs 1 in 5) and reduced disruption to daily activities reported.
Key point: Phase 4 COMPARE study (n=1,000) found lower systemic and local reactogenicity for Nuvaxovid vs mRNA-1283 comparator.
Implication: May influence vaccine choice where tolerability affects uptake behavior.
🧫 Moderna advances H5 influenza vaccine into Phase 3 [6] [21 Apr 2026]
https://feeds.issuerdirect.com/news-release.html?newsid=7750898640724229&symbol=MRNA
Context: Supported by CEPI funding; evaluates safety and immunogenicity in healthy adults.
Key point: Phase 3 trial of mRNA-1018 enrolling ~4,000 adults in US and UK for pandemic influenza preparedness.
Implication: May strengthen rapid-response vaccine capacity for emerging influenza strains.
💊 EU approves Moderna flu–COVID combination vaccine [7] [21 Apr 2026]
https://feeds.issuerdirect.com/news-release.html?newsid=6037570860109793&symbol=MRNA
Context: Phase 3 trial (~8,000 participants total across cohorts) supported authorization across EU.
Key point: mRNA-1083 (mCOMBRIAX) approved for adults ≥50 years, showing non-inferior and in some cases superior immune responses vs comparators.
Implication: May simplify seasonal respiratory immunization in older populations.
🧬 First-in-human ovarian cancer mRNA vaccine trial approved [8] [23 Apr 2026]
https://www.epitopea.com/epitopea-announces-approval-of-ovact-clinical-trial-application-for-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer/
Context: Off-the-shelf RNA vaccine targeting tumor-specific antigens identified via CryptoMap platform.
Key point: Epitopea receives MHRA approval for Phase 1/1b OVACT trial of CryptiVax-1001 in high-grade serous ovarian cancer.
Implication: May expand off-the-shelf cancer immunotherapy approaches beyond personalized vaccine formats.
Why it matters
- Early clinical signals continue to support expansion of mRNA vaccines into oncology and infectious disease prevention
- Real-world evidence (RSV) is reinforcing timing-sensitive maternal immunization strategies
- Regulatory momentum in respiratory vaccines is broadening platform use cases (single-dose and combination products)
- AI-guided antigen selection is increasingly central in personalized cancer vaccine development
- Comparative tolerability data is becoming a key factor in vaccine adoption dynamics
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Vaccines archive on our research hub page.
FAQ
What is most important from the RSV study? [1]
It is a large real-world dataset showing high effectiveness (>80%) in preventing infant hospitalisation, reinforcing antenatal vaccination timing.
Are mRNA cancer vaccines proven yet? [2][4]
No. Both MSK and Evaxion datasets are early-stage signals showing immune activation and survival associations, but require larger controlled trials.
What does the chikungunya vaccine result show? [3]
Strong immunogenicity and durability after a single dose in Phase 1, but efficacy in real-world prevention has not yet been established.
Why is reactogenicity comparison important in COVID vaccines? [5]
Side effect profiles can influence vaccine uptake and willingness to receive repeat annual vaccination.
What is the significance of Moderna’s combination vaccine? [7]
It may reduce the number of injections needed for seasonal respiratory protection, potentially improving coverage in older adults.
Entities / Keywords
RSV maternal vaccine, UKHSA, MSKCC, autogene cevumeran, Valneva VLA1553, chikungunya vaccine, Evaxion EVX-01, AI-Immunology, Sanofi Nuvaxovid, mNEXSPIKE, Moderna mRNA-1018, mCOMBRIAX, Epitopea CryptiVax-1001, ovarian cancer vaccine, CEPI, mRNA immunotherapy
References